Junko Hirata

Tokorozawa, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients.

Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients.

Journal: Oncology
Published: December 18, 2018

Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas.

Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas.

Journal: Oncology
Published: May 22, 2018

JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.

JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.

Journal: Oncology letters
Published: June 08, 2017

Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.

Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.

Journal: Cancer chemotherapy and pharmacology
Published: January 25, 2017

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.

Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.

Journal: Oncology
Published: October 27, 2016

Factors favouring long-term survival following recurrence in ovarian cancer.

Factors favouring long-term survival following recurrence in ovarian cancer.

Journal: Molecular and clinical oncology
Published: August 17, 2016

Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.

Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.

Journal: Molecular and clinical oncology
Published: August 11, 2016

Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Journal: Molecular and clinical oncology
Published: March 09, 2016

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

Journal: British journal of cancer
Published: September 29, 2014

UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.

UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.

Journal: European journal of gynaecological oncology
Published: June 21, 2013

Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell type to grade 3 endometrioid-type.

Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell type to grade 3 endometrioid-type.

Journal: European journal of gynaecological oncology
Published: January 19, 2013

Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy.

Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy.

Journal: Oncology letters
Published: March 16, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026